Amanta Healthcare Limited IPO Opens on September
01, 2025
Total Issue Size - Up To 1,00,00,000 Equity Shares of face
value ₹ 10 each
IPO Size - ₹ 12,600.00 Lakhs (At Upper Price Band)
Price Band - ₹ 120 - ₹ 126 Per Share
Lot Size – 119 Equity Shares
Amanta Healthcare Limited, a pharmaceutical company engaged in
development, manufacturing, and marketing of sterile liquid products, including
both large and small volume parenterals (LVPs and SVPs), proposes to open its
Initial Public Offering on September 01, 2025, aiming to raise ₹ 12,600.00 Lakhs (at upper price band) with
shares to be listed on the NSE and BSE Platform.
The issue
size is up to 1,00,00,000 equity shares with a face value of ₹ 10 each with a price band of ₹ 120 - ₹ 126 Per Equity
Share.
Equity Share
Allocation
- Qualified Institutional Buyer – Not more than 50,00,000 Equity Shares
- Non-Institutional Investors - Not less than 15,00,000 Equity Shares
- Individual
Investors - Not less than 35,00,000 Equity Shares
The net proceeds from the IPO will be utilized
for funding capital expenditure requirements for civil construction work and
towards purchase of equipment, plant and machinery for setting up new
manufacturing line of SteriPort at Hariyala, Kheda,
Gujarat, funding capital expenditure requirements towards civil construction
work, purchase of equipment, plant and machinery for setting up new
manufacturing line for SVP at Hariyala, Kheda, Gujarat, and general corporate purposes.
The anchor portion will open on Friday, August 29, 2025 and issue will
close on Wednesday, September 03, 2025.
The Book Running Lead Manager to the Issue is Beeline
Capital Advisors Private Limited, and the Registrar is MUFG Intime India Private Limited
(Formerly Known as Link Intime India Private Limited).
Mr. Bhavesh Patel, Chairman and Managing Director of Amanta Healthcare
Limited expressed,“Our company has
grown by developing and supplying a wide range of sterile liquid products
across therapeutic segments and medical devices. We have established a presence
across domestic and international markets. This IPO marks a step forward in our
growth journey, allowing us to expand our manufacturing capabilities with new
SteriPort and SVP lines at our Hariyala facility, which will strengthen our capacity
and support us for Future plans.”
About Amanta Healthcare Limited
Amanta Healthcare Limited, a
pharmaceutical company engaged in developing, manufacturing, and marketing of
sterile liquid products, including both large and small volume parenterals
(LVPs and SVPs) using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow
Moulding (ISBM) technologies, The Company serve’s six therapeutic segments such
as fluid therapy - (IV
Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions. The
company also manufacture medical devices like irrigation solutions, first-aid
products, and eye lubricants. Our packaging includes a wide range of closure
systems and container volumes from 2 ml to 1000 ml.
Amanta is led by experienced Management including Mr.
Bhavesh Patel who is the Promoter, chairman and managing director of the
company–. He is a Mechanical Engineer and holds a master’s degree in management
with more than 30 years of experience.
In FY25, The Company achieved a
Revenue of ₹ 27,470.82 Lakhs, EBITDA of
₹ 6,105.37 Lakhs & PAT
of ₹ 1,050.07 Lakhs.
Disclaimer:
Certain
statements in this document that are not historical facts are forward looking
statements. Such forward-looking statements are subject to certain risks and
uncertainties like government actions, local, political or economic
developments, technological risks, and many other factors that could cause
actual results to differ materially from those contemplated by the relevant
forward-looking statements. The Company will not be in any way responsible for
any action taken based on such statements and undertakes no obligation to
publicly update these forward-looking statements to reflect subsequent events
or circumstances.
